StockNews.AI
COYA
StockNews.AI
103 days

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

1. Dieter Weinand appointed Chairman of Sibylla Biotech Board. 2. Weinand brings over 35 years of experience in pharmaceuticals. 3. Sibylla's PPI-FIT technology aims to address undruggable targets. 4. Weinand's leadership is expected to advance preclinical studies. 5. COYA's board member role for Weinand may positively link both companies.

6m saved
Insight
Article

FAQ

Why Bullish?

Weinand’s extensive pharmaceutical experience can enhance Sibylla's strategic direction, potentially benefiting COYA as well, especially given his board presence. Historical examples show that strong leadership can significantly boost investor confidence in biotech firms, as seen with companies like Moderna when they had effective leaders during critical growth phases.

How important is it?

The appointment of an influential figure like Weinand can significantly influence industry perceptions, and since he is connected to COYA, this creates a direct impact channel. COYA's association with Sibylla could position it favorably among investors looking for potential growth opportunities in innovative biotech.

Why Long Term?

The long-term impact arises from the strategic advancements in biomedical technology that Sibylla aims to achieve under Weinand’s leadership. Such advancements may eventually lead to successful collaborations or technology sharing with COYA, impacting their performance positively over time.

Related Companies

REPLSIBYMRNA
Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand’s profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of challenging therapeutic areas.   “Having an industry leader of Dieter’s stature head our Board underscores the potential of Sibylla’s technology to reshape the drug discovery landscape by unlocking access to a range of previously undruggable targets. Dieter’s demonstrated success in driving value from R&D to the commercialization of impactful medicines will guide the next stages of Sibylla’s growth as we advance our pipeline of folding interference small molecules in preclinical studies. Personally, I will be honored to have him at our side,” said Lidia Pieri, PhD, MBA, Co-Founder and Chief Executive Officer of Sibylla Biotech. “Sibylla’s unique approach to targeting protein degradation during the folding process has the opportunity to revolutionize this field and open new avenues for recognized but currently inaccessible targets across high-need diseases. The company has made strides in growing the organization, progressing its technology and securing strategic drug discovery collaborations. I look forward to working with the team to reach new corporate and clinical milestones,” added Dieter Weinand, Chairman of the Board of Sibylla Biotech. With a career marked by significant achievements across pharmaceutical development, commercialization and global leadership, Mr. Weinand has established himself as a prominent industry veteran. He most recently led the Global Primary Care Business at Sanofi, where he optimized the company’s portfolios. As President, CEO and Chairman of the Board at Bayer Pharmaceuticals AG, Mr. Weinand oversaw the integration of R&D, manufacturing, and all commercial and support functions for the healthcare division, thereby executing critical growth strategies. Mr. Weinand has held significant senior management roles at Bristol-Meyers Squibb, Pfizer and other leading big pharma companies. His contributions have been essential to the launch of several high-impact medicines, including Lipitor®, Neurontin®, Abilify® and Cipro®. Mr. Weinand holds a B.A. in Biology from Concordia College, New York, and an M.S. in Pharmacology and Toxicology from Long Island University, New York. He serves as Chairman of the Board at companies including Confo Therapeutics, DISCO Pharmaceuticals and FORE Biotherapeutics. In addition, he is the Lead Independent Director at Replimune (Nasdaq: REPL) and a Board Member at Coya Therapeutics (Nasdaq: COYA). About Sibylla BiotechSibylla is transforming drug discovery by targeting protein folding intermediates, a new druggable dimension in the pharmacological space. Unlike most drugs that act on native proteins, we intervene earlier-targeting proteins before they become undruggable. Thanks to our proprietary technology platform, PPI-FIT, we can predict and target intermediate steps in the protein folding process. Our small molecule drugs interfere with the folding process, leading to targeted protein degradation through the physiological pathway. Sibylla is building an exciting pipeline of treatments for diseases with high medical need across multiple therapeutic areas, with the mission to bring protein folding interference therapeutics to patients. For further information: https://www.sibyllabiotech.it/ Sibylla Biotech Contact Lidia Pieri+39 347 6499534lidia.pieri@sibyllabiotech.it Sibylla Biotech Media Contact Trophic CommunicationsValeria Fisher +49 175 80 41 816 fisher@trophic.eu 20250508_Sibylla_DW Chairman_EN Headshot of Dieter Weinand Headshot of Dieter Weinand Dieter Weinand, Chairman of the Board of Sibylla Biotech

Related News